Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

3.970 -0.080 (-1.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 195,862
Open 4.150
Bid (Size) 3.860 (200)
Ask (Size) 4.440 (500)
Prev. Close 4.050
Today's Range 3.645 - 4.720
52wk Range 4.040 - 23.25
Shares Outstanding 24,887,446
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its... 
Via TheNewswire.com

Performance

YTD
-59.5%
-59.5%
1 Month
-31.4%
-31.4%
3 Month
-58.7%
-58.7%
6 Month
-61.0%
-61.0%
1 Year
-73.8%
-73.8%

More News

Read More
News headline image
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Receives USD$2.6 Million Tax Rebate Payment
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Receives USD$2.6 Million Tax Rebate Payment
Via TheNewswire.com
News headline image
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Enters a Material Transfer Agreement With PegBio
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Effective Date for Reverse Stock Split
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Updates Business Development
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Via ACCESS Newswire
News headline image
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Via ACCESS Newswire
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Via ACCESS Newswire
News headline image
Lexaria Bioscience Releases Second Episode of Investor Video Series
Via ACCESS Newswire
News headline image
Lexaria Updates Progress on Human Study #7
Via ACCESS Newswire
News headline image
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Via ACCESS Newswire
Wednesday's session: top gainers and losers ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Via ACCESS Newswire
News headline image
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Via ACCESS Newswire
News headline image
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Via ACCESS Newswire
News headline image
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Via ACCESS Newswire

Frequently Asked Questions

Is Lexaria Bioscience Corp. - Common Stock publicly traded?
Yes, Lexaria Bioscience Corp. - Common Stock is publicly traded.
What exchange does Lexaria Bioscience Corp. - Common Stock trade on?
Lexaria Bioscience Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexaria Bioscience Corp. - Common Stock?
The ticker symbol for Lexaria Bioscience Corp. - Common Stock is LEXX on the Nasdaq Stock Market
What is the current price of Lexaria Bioscience Corp. - Common Stock?
The current price of Lexaria Bioscience Corp. - Common Stock is 3.970
When was Lexaria Bioscience Corp. - Common Stock last traded?
The last trade of Lexaria Bioscience Corp. - Common Stock was at 09/11/26 04:00 PM ET
What is the market capitalization of Lexaria Bioscience Corp. - Common Stock?
The market capitalization of Lexaria Bioscience Corp. - Common Stock is 98.80M
How many shares of Lexaria Bioscience Corp. - Common Stock are outstanding?
Lexaria Bioscience Corp. - Common Stock has 99M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.